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Objective: To estimate mortality in HIV-positive patients starting combination antiretroviral therapy (ART) and to discuss different approaches to calculating correction
factors to account for loss to follow-up.
Methods: A total of 222 096 adult HIV-positive patients who started ART 2009–2014 in
clinics participating in the International epidemiology Databases to Evaluate AIDS
collaboration in 43 countries in sub-Saharan Africa, Asia Pacific, Latin America, and
North America were included. To allow for underascertainment of deaths due to loss to
follow-up, two correction factors (one for the period 0–6 months on ART and one for
later periods) or 168 correction factors (combinations of two sexes, three time periods
after ART initiation, four age groups, and seven CD4þ groups) based on tracing patients
lost in Kenya and data linkages in South Africa were applied. Corrected mortality rates
were compared with a worst case scenario assuming all patients lost to follow-up had
died.
Results: Loss to follow-up differed between regions; rates were lowest in central Africa
and highest in east Africa. Compared with using two correction factors (1.64 for the
initial ART period and 2.19 for later), applying 168 correction factors (range 1.03–4.75)
more often resulted in implausible mortality rates that exceeded the worst case scenario.
Corrected mortality rates varied widely, ranging from 0.2 per 100 person-years to 54 per
100 person-years depending on region and covariates.
Conclusion: Implausible rates were less common with the simpler approach based on
two correction factors. The corrected mortality rates will be useful to international
agencies, national programmes, and modellers.
Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
The survival of HIV-positive patients on antiretroviral
therapy (ART) is an important indicator of ART
programmes’ effectiveness and is key to informing public
health policy [1,2]. Estimations of mortality in HIVpositive patients on ART rely on the complete
ascertainment of deaths. However, many patients starting
ART are lost to follow-up, especially in sub-Saharan
Africa, and their mortality is typically higher compared
with patients retained in care [3–5]. Deaths among
patients lost to follow-up are not generally recorded,
leading to underestimation of overall, programme-level
mortality. Several correction methods to reduce this bias
have been proposed [6–8], which rely on vital status
information of a sample of patients lost to follow-up
obtained through tracing or data linkages with civil
registries [4,5,9].
The International epidemiology Databases to Evaluate
AIDS (IeDEA) collaboration is a consortium of HIV
cohort studies and clinical databases with regional
networks in sub-Saharan Africa, North and Latin
America, and Asia Pacific [10–12]. IeDEA is an
important source of regional HIV/AIDS data, which
has been used, for example, in the Spectrum projection
package (Avenir Health, Glastonbury, CT, USA) developed for the Joint United Nations Program on HIV/
AIDS (UNAIDS) [13]. Spectrum is a modelling package
that supports national programmes to make annual
estimates of the number of people living with HIV by
age and sex, the number of new infections and AIDS
deaths, and the need for ART and its impact [13,14].
In 2012, the IeDEA consortium provided UNAIDS with
mortality estimates for patients on ART for use in the
Spectrum projection package [8]. In that study, a twostage approach was used to adjust for biases in mortality
estimation resulting from loss to follow-up. Initially,
correction factors were determined on the basis of data
from programmes tracing patients lost to follow-up in
Kenya [15] and from linkages with population registries in
South Africa [9]. Then the correction factors were
applied to adjust mortality rates from other regions [8].
The aim of this analysis is to update the previous estimates
and to refine and study the mortality correction methods.

Methods
Data sources
We included longitudinal patient-level data from HIV
cohorts in the seven regions of the IeDEA collaboration:
central Africa, east Africa, southern Africa, west Africa,
Asia Pacific, Latin America (Caribbean, central, and
South America), and North America [10–12]. Fortythree countries contributed data: Rwanda, Burundi, and
Democratic Republic of the Congo (central Africa);

Uganda, Kenya, and Tanzania (east Africa); South Africa,
Zambia, Zimbabwe, Malawi, Lesotho, and Mozambique
(southern Africa); Côte d’Ivoire, Nigeria, Togo, Burkina
Faso, Mali, Benin, Guinea-Bissau, Senegal, and Guinea
(west Africa); India, Singapore, Cambodia, Vietnam,
Thailand, Hong Kong, Philippines, Malaysia, Taiwan,
Japan, Republic of Korea, China, and Indonesia (Asia
Pacific); Haı̈ti, Peru, Brazil, Chile, Argentina, Mexico,
and Honduras (Latin America); and USA and Canada
(North America). In all of the cohorts, data were
collected at enrolment, ART initiation, and at each
follow-up visit. Pooling of data and their use in
collaborative analyses was approved by local ethics
committees and institutional review boards.
For two of the regions, data included information about
outcomes in patients lost to follow-up: the cohorts from
the Republic of South Africa had linked their patients to
the national death registry, and cohorts in Kenya carried
out tracing of patients lost to follow-up to ascertain their
vital status. For the other countries of the east and
southern African regions and the five other regions, no
information on mortality in patients lost to follow-up was
available. In North America and Latin America, some
cohorts linked patients to vital registries and updated the
outcomes of these patients in their databases. However,
they did not record whether or not a death was
ascertained through linkage to a vital registry.

Inclusion criteria, collection of variables, and
definitions
We included patients aged at least 15 years who were ARTnaı̈ve at enrolment, started ART between 2009 and 2014,
and had at least 1 day of follow-up. ART was defined as a
combination of at least three antiretroviral drugs. Data
included patient sex, age, CD4þ cell count at start of ART,
date of starting ART, and outcome. The CD4þ cell count
at ART start was defined as the measurement closest to the
date of starting therapy within a window of 182 days before
and 14 days after ART initiation. To match the structure of
the Spectrum model, age was grouped into four categories
(15–24, 25–34, 35–44, and 45 years) and CD4þ cell
count at ART start into seven categories (<50, 50–99,
100–199, 200–249, 250–349, 350–499, and 500 cells/
ml). Outcomes included death and loss to follow-up.
Patients were considered lost to follow-up if their last visit
was more than 182 days prior to database closure and there
was no record of their death or transfer [16]. The Kenyan
cohorts recorded whether a patient had been traced or not,
and the South African linkage cohorts recorded whether a
patient had a valid South African civil identification
(ID) number.
Estimation of crude mortality rates
We used exponential survival models to estimate
mortality rates not adjusted for loss to follow-up. We
assumed a piecewise constant hazard for three time
periods (0–6, 6–12, and 12 months after starting ART)
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and included the covariates sex, age, and CD4þ cell count
at ART start. In addition, we modelled the period 0–6
months separately from the other two periods to allow for
potentially different effects of covariates on mortality
shortly after starting treatment. The follow-up of all
patients without a death record was administratively
censored at the last visit in the unadjusted analysis. Models
were fit using the penalized maximum likelihood
estimation procedure proposed by Gertheiss and Tutz
[17], which accounts for the ordinal nature of the CD4þ
covariate. This procedure smoothes coefficients across
categories of the CD4þ cell count at ART start so that
they become more similar to those of adjacent CD4þ cell
count categories, which reduces overfitting and improves
prediction. We determined the penalization parameter for
each region separately, minimizing deviances in a 10-fold
cross-validation.

Correction for loss to follow-up
We multiplied the crude mortality rates by correction
factors to adjust them for loss to follow-up. We calculated
three different sets of correction factors, one from the
Kenyan tracing data and two from the South African
linkage data. For Kenya, we determined the correction
factors in the same way as in 2012 [8]: first we calculated
crude mortality rate estimates for all subgroups by fitting
the survival model and treating patients lost to follow-up
as administratively censored. Then, we included the
ascertained outcomes of traced patients, weighted
observations as proposed by Frangakis and Rubin [18],
and fitted the model to the updated data to obtain
adjusted mortality rate estimates. The correction factors
were derived by dividing the adjusted rate estimates by the
crude estimates. This led to a Kenyan set of 168
correction factors, one for each covariate subgroup (two
sexes  three time periods  four age groups  seven
CD4þ groups).
For the South African data, we fitted the survival model
including an additional covariate, which indicated
whether or not a patient had an ID and was therefore
linkable to the vital registry. The first of the two sets of
correction factors was defined as the estimated effect of
this linkage indicator. This entailed two correction
factors, one for the initial ART period (0–6 months) and
one for later ART, which were modelled separately. In a
further analysis, we allowed for two-way interactions
between the linkage indicator and the other covariates.
We then defined the correction factors as the estimated
effect of the linkage indicator and its interactions. As with
Kenya, this resulted in a set with 168 correction factors. In
contrast to Kenya, this approach allowed statistical testing
of whether the inclusion of any of the two-way
interactions improved the model.

Measuring variability
We used the bootstrap case resampling method for
regression analyses to generate sampling errors both for

crude mortality rate estimates and correction factors.
Assuming independence of the two, we derived the total
variance around the adjusted mortality estimates by
adding the two variances.

Sensitivity analyses
We used sensitivity analyses to gauge the plausibility of
corrected mortality rate estimates. We compared the
three sets of corrected mortality rates with crude estimates
and estimates from worst and best case scenarios. The
worst case scenario assumed that all patients lost to followup had died at their last visit. The best case scenario
assumed that all patients lost to follow-up were alive at
database closure.

Results
Selection of eligible patients
After excluding patients with missing CD4þ cell count at
the start of ART or no follow-up visit after ART was
initiated, 222 096 patients were included in the analyses
(Table 1): 8043 from central Africa, 61 315 from east
Africa, 109 434 from southern Africa, 21 713 from west
Africa, 7425 from Asia Pacific, 7017 from Latin America,
and 7149 from North America. A total of 30 292 patients
were enrolled in Kenyan cohorts with tracing programmes and 35 674 South African patients in cohorts in
which vital registry linkage was available. Of these 35 674
patients, 13 749 (39%) had no ID and could not be linked.
Baseline characteristics and loss to follow-up
For all African regions, the proportion of women among
all patients initiating ARTwas about twice the proportion
of men, whereas for non-African regions the opposite
was the case (Table 1). The median age at the start of ART
ranged from 33 years in the east African cohorts without
tracing to 39 years in North America. The median CD4þ
cell count at ART initiation ranged from 157 cells/ml in
southern African cohorts with vital registry linkage to
336 cells/ml in North America.
Rates of loss to follow-up differed widely between
regions. Rates were lowest in central Africa and highest in
east Africa (Table 2). For all African regions, rates of loss
to follow-up declined with longer ART duration. In
non-African regions, the decline was less consistent: in
Asia Pacific, the rate of loss to follow-up was highest in
the first 6 months of ART but stayed constant afterwards,
in North America rates declined slightly, and in Latin
America the rate of loss to follow-up stayed
fairly constant.

Crude mortality rate estimates
Crude mortality rates were generally highest in southern
Africa; slightly lower in east and west Africa; lower in
central Africa, Latin America, and Asia Pacific; and clearly
lowest in North America (Supplementary Tables S1–S7,
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11 365 (37%)
19 658 (63%)
(27–40)
(12%)
(40%)
(30%)
(18%)
(96–324)
(15%)
(11%)
(23%)
(11%)
(21%)
(11%)
(8%)

33
3604
12 537
9400
5482
207
4565
3456
6997
3448
6473
3513
2571

34 (28–42)
1053 (13%)
3185 (40%)
2409 (30%)
1396 (17%)
(cells/ml)
275 (174–342)
450 (6%)
556 (7%)
1425 (18%)
938 (12%)
2923 (36%)
961 (12%)
790 (10%)

31 023

2695 (34%)
5348 (66%)

8043

198
7586
9176
20 523
9938
17 141
5802
3594

35
7491
28 820
23 690
13 759
(108–295)
(10%)
(12%)
(28%)
(13%)
(23%)
(8%)
(5%)

(29–42)
(10%)
(39%)
(32%)
(19%)

27 172 (37%)
46 588 (63%)

73 760

Southern Africa
(no linkage)

181
3676
2707
5432
2610
4076
1825
1387

37
1324
7651
7517
5221

East Africa
(no tracing)

Southern Africa
(no linkage)
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ART, antiretroviral therapy, CI, confidence interval, IQR, interquartile range.
a
Based on patients who could not be linked to the vital registry.

Loss to follow-up rate (95% CI) (per 100 person-years)
<6 months ART
7.3 (6.5–8.3)
27.0 (26.1–27.9) 14.9 (14.5–15.3)
6–12 months ART 6.4 (5.6–7.3)
15.0 (14.2–15.7) 7.9 (7.5–8.2)
12 months ART
5.4 (5.0–5.8)
9.3 (8.9–9.6)
6.3 (6.1–6.5)
Median years on ART before lost to follow-up (IQR)
1.34 (0.55–2.39) 0.60 (0.19–1.44) 0.76 (0.21–1.86)

Central Africa

170
1631
973
1594
857
1471
591
308

37
516
2617
2644
1648
(58–283)
(22%)
(13%)
(21%)
(12%)
(20%)
(8%)
(4%)

(31–44)
(7%)
(35%)
(36%)
(22%)

5097 (69%)
2328 (31%)

7425

Asia Pacific

Asia Pacific

(85–205)
(16%)
(11%)
(20%)
(12%)
(28%)
(9%)
(4%)

(29–44)
(12%)
(36%)
(30%)
(23%)

Latin America

210
1149
772
1422
827
1952
620
275

36
816
2505
2102
1594

4348 (62%)
2669 (38%)

7017

Latin America

336
677
406
787
551
1336
1702
1690

39
840
2056
1906
2347

North
America

(190–488)
(9%)
(6%)
(11%)
(8%)
(19%)
(24%)
(24%)

(30–48)
(12%)
(29%)
(27%)
(33%)

5473 (77%)
1676 (23%)

7149

North
America

(74–279)
(18%)
(14%)
(25%)
(12%)
(20%)
(7%)
(5%)

(30–45)
(7%)
(30%)
(34%)
(29%)

(29–42)
(9%)
(41%)
(32%)
(18%)
157 (80–231)
5662 (16%)
5447 (15%)
12 213 (34%)
5132 (14%)
5367 (15%)
1172 (3%)
681 (2%)

35
3321
14 725
11 254
6374

12 603 (35%)
23 071 (65%)

35 674

Southern Africa
(linkage)

East Africa
(tracing)

Southern Africa
(linkage)a

Regions with linkage or tracing

173
5489
4127
7663
3522
5986
1970
1535

37
2001
9170
10 302
8819

10 849 (36%)
19 443 (64%)

30 292

East Africa
(tracing)

1.11 (0.39–2.54) 1.17 (0.37–2.32) 1.46 (0.64–2.34) 1.07 (0.46–1.95) 0.68 (0.24–1.52) 0.63 (0.24–1.44)

21.9 (21.0–22.8) 18.0 (16.7–19.5) 13.2 (12.0–14.5) 16.7 (15.4–18.2) 53.0 (51.8–54.3) 29.5 (28.1–31.0)
12.7 (11.9–13.5) 10.6 (9.5–11.9) 11.9 (10.7–13.2) 16.4 (14.9–18.0) 34.0 (32.9–35.2) 20.0 (18.7–21.5)
10.8 (10.4–11.1) 10.6 (10.0–11.3) 13.7 (12.9–14.4) 15.8 (14.8–16.7) 23.3 (22.7–23.9) 17.0 (16.1–17.9)

West Africa

Regions without linkage or tracing

(82–291)
(17%)
(12%)
(25%)
(12%)
(19%)
(8%)
(6%)

(31–45)
(6%)
(35%)
(35%)
(24%)

7193 (33%)
14 520 (67%)

21 713

West Africa

Table 2. Rates of loss to follow-up and duration of antiretroviral therapy by region.

IQR, interquartile range.

No. of patients
Sex
Male
Female
Age (years)
Median (IQR)
15–24
25–34
35–44
45þ
CD4þ cell count
Median (IQR)
<50
50–99
100–199
200–249
250–349
350–499
500

East Africa
(no tracing)

Regions with linkage or tracing

AIDS

Central Africa

Regions without linkage or tracing

Table 1. Patient characteristics at the start of antiretroviral therapy by region.
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http://links.lww.com/QAD/B7). Crude mortality was
highest in patients with CD4þ cell counts less than 50
cells/ml at ART initiation and declined with increasing
CD4þ cell count, although the decline was only modest
for the highest four CD4þ categories. Crude mortality
was highest in the first 6 months after starting therapy for
all regions except North America, where mortality did
not vary much by duration of therapy.

death was less pronounced in the first 6 months of ART
duration. The South African set with 168 correction
factors contained some high values and implausible
patterns, for example, for CD4þ categories 350–499 and
at least 500 cells/ml (where sample sizes were small).
None of the two-way interactions included in the model
was statistically significant (P > 0.05). The Kenyan set of
168 correction factors also showed some unexpected
patterns, most likely due to small sample sizes in some of
the combinations of ART duration, sexes, age groups,
and CD4þ groups.

Correction factors and sensitivity analysis
The three sets of correction factors are illustrated in Fig. 1
and given in Supplementary Table S8, http://links.lww.
com/QAD/B7. The South African set with two
correction factors implied that underascertainment of

Implausible corrected mortality rates that exceeded the
worst case scenario were observed for southern Africa,

South Africa
female

Kenya
male

female

4

4

3

2

2

1

1

4

4

25−34

25−34

3

15−24

15−24

3

3

2

Correction factor

2

Correction factor

male

1

4

1

4

3

2

2

1

1

4

4

2

45+

45+

3

35−44

35−44

3

3

2

1

1
0−6 months 6−12 months >12 months

0−6 months 6−12 months >12 months

0−6 months 6−12 months >12 months

ART duration

0−6 months 6−12 months >12 months

ART duration

CD4
category

<50

100−199

250−349

50−99

200−249

350−499

>=500

Fig. 1. Correction factors. The South African set of two correction factors is shown in black, the two sets of 168 correction factors
derived from the South African and Kenyan data are shown in colour.
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Table 3. Implausible corrected mortality rates exceeding the worst case scenario estimates, by set of correction factors used.
South African correction factors
Set of 2
Southern Africaa
Central Africa
Latin America
Asia Pacific
East Africa
West Africa
North America

6/168
4/168
5/168
1/168
0/168
0/168
0/168

(3.6%)
(2.4%)
(3.0%)
(0.6%)
(0%)
(0%)
(0%)

Kenyan correction factors

Set of 168
7/168
5/168
5/168
1/168
0/168
0/168
0/168

(4.2%)
(3.0%)
(3.0%)
(0.6%)
(0%)
(0%)
(0%)

Set of 168
10/168
10/168
7/168
2/168
0/168
0/168
0/168

(6.0%)
(6.0%)
(4.2%)
(1.2%)
(0%)
(0%)
(0%)

a

Nonlinkage cohorts only.

central Africa, Latin America, and Asia Pacific. There
were 16 such instances for mortality corrections with the
South African set of two correction factors, 18 instances
with the South African set of 168 factors, and 29 with the
Kenyan set of 168 factors (Table 3). Some of these
implausible rates are shown in Fig. 2, panels a–d. In west
Africa, North America, and east Africa, worst case
mortality estimates were high, and none of the corrected
rates exceeded them (Fig. 2, panels e–g). There were no
correction factors below 1; therefore, no corrected
mortality rate estimates fell below the best case scenario.

Final corrected mortality rates
In the final analysis, we used the South African set of two
correction factors to adjust mortality rates in all regions
except in east Africa, where we used the Kenyan set of
168 correction factors. The corrected mortality rate
estimates with bootstrapped 95% confidence intervals,
which are used in the newest update of the Spectrum
projection package, are reported in Supplementary Tables
S9–S15, http://links.lww.com/QAD/B7. Similar patterns as described above for the crude mortality estimates
were evident in the corrected estimates.

Discussion
Estimates of mortality and life expectancy in HIV-positive
populations rely on the complete ascertainment of deaths.
However, the proportion of patients lost to follow-up in
HIV care programmes is high, especially in sub-Saharan
Africa [3]. Patients who are lost to follow-up typically
experience higher rates of mortality than those remaining
in care [4,5], so failing to account for deaths among all
patients who started ART leads to an underestimation of
overall, programme-level mortality. Use of information
from tracing patients lost to follow-up and linkages with
vital registries has repeatedly resulted in upward revision
of mortality estimates [7,19,20].
In this study, we multiplied crude mortality rates by
correction factors to adjust for biases resulting from loss to
follow-up. We used three different sets of correction
factors that were calculated based on the outcomes of

tracing patients lost to follow-up in Kenya and linkage of
HIV programme data with the national death registry in
South Africa. Corrected mortality estimates differed
depending on the set of correction factors, and
implausible corrected rates were observed with all three
sets. Implausible rates were more common with the two
sets of 168 correction factors than with the simpler
approach based on two factors only. None of the two-way
interactions included in the model for the South African
set of 168 correction factors reached conventional levels
of statistical significance. The poorer performance of the
two large sets of correction factors might therefore be due
to overfitting, which occurred despite using a penalized
maximum likelihood estimation procedure [17] that will
have reduced overfitting to some extent. In the final
analysis, we decided to use the more conservative
approach based on two correction factors only for all
regions except for east Africa. For east Africa, we used the
Kenyan correction factors, as they might better represent
the regional pattern of mortality among patients lost to
follow-up in east Africa.
Compared with the earlier analysis published in 2012 [8],
the mortality estimates calculated in this study were
somewhat higher. This is probably explained by the
different composition of the study population, with a shift
to countries with higher mortality. For example, in the
previous analysis, the Republic of South Africa was the
only country in the southern African region. In the
present study, we also included data from Zambia,
Zimbabwe, Malawi, Mozambique, and Lesotho. Determinants of mortality were however similar for the 2012
and the current analysis, with high mortality rates in the
first 6 months of ART and with low CD4þ cell counts,
which decreased with longer ART duration and higher
CD4þ cell counts. It would be worthwhile to examine
trends over calendar years as recent studies have shown
that in African programmes mortality among patients lost
to follow-up appears to have declined in recent years
[5,21]. This may be due to higher CD4þ cell counts at the
start of ARTand to an increase in undocumented transfers
to other clinics [5,21]. For example, a study in Lilongwe,
Malawi found that among patients lost to follow-up and
found to be alive on tracing, a majority (56%) were still on

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
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(a)

Asia Pacific, male, 15−24 years, CD4 <50

(b) Southern Africa, male, 35−44 years, CD4 50−99
Mortality rate (per 100 PY)

Mortality rate (per 100 PY)
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0
0−6 months

(c)

6−12 months
ART duration

0

>12 months

Central Africa, male, 25−34 years, CD4 <50

(d)

0−6 months

6−12 months
ART duration

>12 months

Latin America, female, 45+ years, CD4 <50
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0
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Fig. 2. Examples of sensitivity analyses for Asia Pacific (a), southern Africa (b), central Africa (c), Latin America (d), west Africa
(e), east Africa (f) and North America (g). The different corrected mortality estimates are compared with worst case scenario
estimates (upper black dashed line) and best case scenario estimates (lower black dashed line) and crude mortality (black dotted
line). Crude mortality and mortality from best case scenario are closely similar.

ART sourced from another clinic [22]. Similarly, a study
of adults starting ART in Uganda, Tanzania, and Kenya
found that 59% of patients interviewed had reconnected
to care at a different clinic [23].
Our study has several limitations. The comparisons with
worst and best case scenarios were useful to detect
implausible mortality rates, but the range between

estimates from the two scenarios was wide. It is impossible
to know with any precision how appropriate mortality
corrections were. In general, by applying correction
factors originating from one region to correct mortality
estimates in another region, we assumed that both
mortality in patients lost to follow-up and rates of loss to
follow-up were similar in the two regions. As determinants and rates of loss to follow-up and mortality differ
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between treatment programmes within and across
countries and regions, it seems unlikely that the situation
in South Africa and Kenya and the correction factors from
these countries accurately capture the underestimation of
mortality rates in other African countries, the Asia Pacific
region, and countries in North or Latin America [8]. This
in turn might be the reason why none of the three sets
achieved corrected mortality estimates that stayed within
best and worst case boundaries in all regions. Also, as in
Latin America and North America, linkage to vital
registries was performed occasionally in some cohorts,
the crude mortality estimates might already capture some
of the mortality of patients lost to follow-up. Applying the
South African correction factors to these regions might
thus result in an overestimation of mortality.

accuracy of corrected mortality estimates for HIVpositive patients who started ART in sub-Saharan Africa,
the region where loss to follow-up is common [3]. Similar
studies in other regions are warranted.

The correction factors themselves might also be subject to
bias: in Kenya and elsewhere, tracing programmes do not
trace a random sample of the patients who were lost to
follow-up but are imbedded into routine patient outreach
efforts [20,24,25]. Moreover, not all patients lost are
successfully located. In a recent systematic review of
tracing studies, we found that about 80% of patients could
be located but this percentage varied widely across studies
[21]. With the linkage data from South Africa, this
problem is less important: bias will only arise if patients
with an ID differ systematically from those without ID,
and the effect of this bias cannot be minimized by the
covariates included in the model. One study found that
patients with ID are similar to the patients without ID in
terms of their demographic and baseline clinical
characteristics [9].
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